By Daniel Furr

Multi-national health care organization Centene Corporation (Centene) recently announced it will be funding up to $100 million in Alzheimer’s research at Washington University School of Medicine. In addition to Alzheimer’s, some of the funding will also help pay for research into breast cancer, diabetes, and obesity, as well. As part of the agreement, Centene’s funds will be distributed over a 10 year period to the university’s Personalized Medicine Initiative. Any innovation emerging from the initiative will be jointly commercialized through both the Washington University School of Medicine and Centene. Centene Corporation, a Fortune 100 company, is a diversified, multi-national health…
Content Restricted

You must be a Free or Elite member to view this resource.

Log In | Sign up or learn more about membership options.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!